Skip to main content
Linda Neuman, MD, Internal Medicine, Waterloo, IL

LindaLouiseNeumanMDMBA

Internal Medicine • Waterloo, IL

Healthcare Research and Healthcare Policy

Chief Medical Officer Aeglea BioTherapeutics

Join to view full profile

Dr. Neuman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Neuman's full profile

Already have an account?

Education & Training

  • St Vincent Hospital and Health Care Center
    St Vincent Hospital and Health Care CenterResidency, Internal Medicine, 1992 - 1994
  • Southern Illinois University
    Southern Illinois UniversityResidency, Internal Medicine, 1991 - 1992
  • Indiana University School of Medicine/Methodist Hospital
    Indiana University School of Medicine/Methodist HospitalInternship, Transitional Year, 1990 - 1991
  • Southern Illinois University School of Medicine
    Southern Illinois University School of MedicineClass of 1990

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1990 - 2026
  • IL State Medical License
    IL State Medical License 1991 - 2026
  • FL State Medical License
    FL State Medical License 1998 - 2005

Clinical Trials

Publications & Presentations

Abstracts/Posters

  • Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice
    Linda Neuman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophili...
    Linda Neuman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

  • Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives
    Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic AlternativesApril 12th, 2023
  • Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer
    Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical OfficerNovember 15th, 2022
  • Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
    Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology ConferenceDecember 7th, 2020
  • Join now to see all

Professional Memberships

Dr. Linda Neuman, Dr. Linda Neuman, MD, Dr. L Neuman, Dr. Linda Louise Neuman